The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Lung Fibrosis

2014 ACR/ARHP Annual Meeting: Lung Fibrosis

February 1, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BOSTON—Patients with idiopathic pulmonary fibrosis (IPF) now have two new drugs available for treatment, and novel targeted treatments are on the horizon.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
Explore This Issue
February 2015
Also By This Author
  • Study Shows Psoriatic Arthritis Impacts Women More Than Men

“The future is bright for the development of treatments for lung fibrosis, especially with an improved understanding of lung fibrosis pathogenesis,” said Flavia Castelino, MD, assistant professor of medicine, Harvard Medical School, Division of Rheumatology, Massachusetts General Hospital, Boston, who moderated the session, Insights into Lung Fibrosis, at the ACR/ARHP Annual Meeting in Boston in November 2014.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Along with approval of two new drugs, new targets for IPF include novel drugs, such as NOX4 inhibitors that target epithelial cell stress and an IL-13 antibody that targets the innate immune system, she said.

New Treatments Approved

In October 2014, the Food and Drug Administration approved pirfenidone and nintedanib based on Phase 3 data showing the safety and efficacy of these drugs for the treatment of IPF.1,2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Timothy Blackwell, MD, director, Division of Allergy, Pulmonary and Critical Care, Department of Medicine, Vanderbilt University School of Medicine, Nashville, spoke on the trial data leading to the approval of these two drugs, both of which were fast tracked for approval ahead of their scheduled application review.

Both nintedanib and pirfenidone were approved on the basis of their established safety and effectiveness in clinical trials of over 1,200 patients with IPF.3,4 These studies showed a significantly improved forced vital capacity (FVC) in patients treated with nintedanib or pirfenidone compared to placebo.

Nintedanib, a kinase inhibitor that blocks multiple pathways involved in scarring of lung tissue, is not recommended in people with moderate to severe liver problems nor in pregnant women. Pirfenidone, which works on multiple pathways involved in scarring of lung tissue, is not recommended for people with severe liver problems or end-stage kidney disease, or those who require dialysis. Patients taking pirfenidone should be advised to take it with food to minimize nausea and dizziness and avoid or minimize exposure to the sun.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Blackwell also spoke about a possible overlap in treatments for IPF and connective tissue lung disease and idiopathic interstitial lung diseases based on lessons learned from familial interstitial pneumonia (FIP), a disease course that is similar to IPF. Genetic studies in FIP show two disease-associated pathways, one that involves surfactant proteins (surfactant protein C or SFTPC and surfactant protein A or SFTPA2) and the other involving telomerase (telomerase reverse transcriptase or TERT, telomerase RNA template or TR, and dyskerin or DKC1).

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Scleroderma Tagged With: AC&R, Annual Meeting, Association of Rheumatology Professionals (ARP), Clinical, fibrosis, Nierengarten, Pulmonary, TreatmentIssue: February 2015

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • Idiopathic Lung Fibrosis—Check for ANCA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)